## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

UMAÑA et al.

Appl. No.: 10/633,699

Filed: August 5, 2003

For: Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular

Cytotoxicity

Confirmation No.: 5489

Art Unit: 1633

Examiner: Burkhart, Michael D.

Atty. Docket: 1975.0010004/TJS/T-M/CFN

Sixth Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Sixth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fifth Supplemental Information Disclosure Statement filed on September 10, 2008, in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication

dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have checked the appropriate boxes below.

- 1. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- Z. Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statement is being filed within three months of the date of filing of a national application other than a continued prosecution application (CPA), OR within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, OR before the mailing date of a first Office Action on the merits OR

before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

- 3. Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.
  - □ a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
  - b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

	□ c.	The required fee is provided through online credit card payment
		authorization in the amount of \$180.00 in payment of the fee
		under 37 C.F.R. § 1.17(p).
□ 4.	Filing under	37 C.F.R. § 1.97(d) This Information Disclosure Statement is being
	_	nan three months after the U.S. filing date and after the mailing date
		tejection or Notice of Allowance, but on or before payment of the
	Issue Fee.	The required fee is provided through online credit card payment
	authorization	n in the amount of \$180.00 in payment of the fee under 37 C.F.R. $\S$
	1.17(p); in a	ddition:
	a.	Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each
		item of information contained in this Information Disclosure
		Statement was first cited in any communication from a foreign
		patent office in a counterpart foreign application not more than
		three months prior to the filing of this Information Disclosure
		Statement. 37 C.F.R. § 1.97(e)(1).
	□ b	. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item
		of information in this Information Disclosure Statement was cited
		in a communication from a foreign patent office in a counterpart
		foreign application and, to my knowledge after making reasonable
		inquiry, was known to any individual designated in 37 C.F.R. §
		1.56(c) more than three months prior to the filing of this

Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

<u></u> 5.	The document(s) was/were cited in a search report by a foreign patent office in a
	counterpart foreign application. Submission of an English language version of
	the search report that indicates the degree of relevance found by the foreign office
	is provided in satisfaction of the requirement for a concise explanation of
	relevance. 1138 OG 37, 38 and MPEP 609.04(a)(III).
☐ 6.	A concise explanation of the relevance of the non-English language document(s)
	appears below in accordance with 37 C.F.R. § 1.98(a)(3).
⊠ 7.	Copies of documents NPL26-NPL31 are submitted. However, in accordance
	with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application
	publications cited on the attached IDS Forms are submitted.
	In addition, copies of documents NPL32-NPL35 are not provided in
	In addition, copies of documents NPL32-NPL35 are not provided in accordance with the U.S. Patent and Trademark Office OG notice of
	accordance with the U.S. Patent and Trademark Office OG notice of
	accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for
	accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each
	accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused
□ 8.	accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is <i>sua sponte</i> waived where the cited pending application is stored
□ 8.	accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is <i>sua sponte</i> waived where the cited pending application is stored in the USPTO's IFW system."
8.	accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is <i>sua sponte</i> waived where the cited pending application is stored in the USPTO's IFW system."  Copies of the documents were cited by or submitted to the Office in an IDS that

- It is expected that the examiner will review the prosecution and cited art in the parent application no(s). 10/437,388 in accordance with MPEP 2001.06(b), and indicate in the next communication from the office that the art cited in the earlier prosecution history has been reviewed in connection with the present application.

In addition, Applicants draw the Examiner's attention to the following U.S. patents and co-pending U.S. applications that may be directed to related subject matter:

Document US7 is listed as U.S. Patent No. 6,602,684, Issued August 5, 2003 (from parent U.S. Appl. No. 09/294,584, Umaña et al., filed April 20, 1999).

Document US8 is listed as U.S. Patent No. 7,517,670, Issued April 14, 2009 (from previously co-pending U.S. Appl. No. 10/633,697, Umaña et al., filed August 5, 2003), previously cited in Applicants' Information Disclosure Statement filed October 13, 2004, as document number AR 45, "United States

Application No. 10/633,697, Umaña et al., filed August 5, 2003 (NOT PUBLISHED)."

Document US9 is listed as U.S. Patent No. 7,662,377, Issued February 16, 2010 (from previously co-pending U.S. Appl. No. 11/889,215, Umaña et al., filed August 9, 2007).

Document **US10** is listed as U.S. Patent No. 7,722,867, Issued May 25, 2010 (from previously co-pending U.S. Appl. No. 11/348,526, Umaña et al., filed February 7, 2006).

Document US11 is listed as U.S. Patent No. 7,727,741, Issued June 1, 2010 (from previously co-pending U.S. Appl. No. 11/892,010, Umaña et al., filed August 17, 2007).

Document US12 is listed as U.S. Patent No. 7,846,432 B2, Issued December 7, 2010 (from previously co-pending U.S. Appl. No. 11/889,981, Umaña et al., filed August 17, 2007).

Document US13 is listed as U.S. Publication No. 2004/0072290, published April 15, 2004 (from co-pending U.S. Appl. No. 10/437,388, Filed: May 14, 2003).

Document US14 is listed as U.S. Publication No. 2005/0123546, published June 9, 2005 (from co-pending U.S. Appl. No. 10/981,738, Filed: November 5, 2004).

Document US15 is listed as U.S. Publication No. 2009/0010921, published January 8, 2009 (from co-pending U.S. Appl. No. 10/889,975, Filed: August 17, 2007).

Document US16 is listed as U.S. Publication No. 2009/0304690, published December 10, 2009 (from co-pending U.S. Appl. No. 12/409,349, filed March 23, 2009).

Document NPL32 is listed as "Co-pending Application, U.S. Application No. 12/724,386, inventors Umaña et al., filed March 15, 2010, not yet published."

Document NPL33 is listed as "Co-pending Application, U.S. Application No. 12/790,716, inventors Umaña et al., filed May 28, 2010, not yet published."

Document NPL34 is listed as "Co-pending Application, U.S. Application No. 12/790,715, inventors Umaña et al., filed May 28, 2010, not yet published."

Document NPL35 is listed as "Co-pending Application, U.S. Application No. 12/938,180, inventors Umaña et al., filed November 2, 2010, not yet published."

The identification of these applications and Office Actions is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Timothy J. Shea, Jr.
Attorney for Applicants

Registration No. 41,306

Date: December 23, 2010

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

1300130\_1.DOC